AstraZeneca Buys U.S. Lung Drug Firm Pearl for Up to $1.15 Billion

AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making, Reuters reported.

DealsNorth AmericaUSBriefs